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Abstract
Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially 
curable stages. Nevertheless, around 20–30% of patients will relapse despite appropriate locoregional and systemic therapies. 
A better knowledge of this disease is improving our ability to select the most appropriate therapy for each patient with a 
recent diagnosis of an early stage breast cancer, minimizing unnecessary toxicities and improving long-term efficacy.
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Abbreviations
ET  endocrine therapy
TAILORx  Trial Assigning Individualized Options for 
Treatment
MINDACT  Microarray in Node-Negative and 1 to 3 
Positive lymph Node Disease may Avoid 
Chemotherapy EORTC 10041/BIG 3-04 
study
DCIS  ductal carcinoma in situ
Introduction
Breast cancer is a major public health problem due to its 
high incidence, prevalence, and mortality. It is by far the 
most common cancer among women in Spain (2012), 
accounting for 29% of all new cases of cancer in females. 
Moreover, it is the first cause of cancer-related mortality in 
the female population, accounting for 15.5% of female can-
cer deaths, and the 5-year prevalence is 40.8% [1].
Breast cancer is a heterogeneous disease with multiple 
intrinsic tumor subtypes [2]. Up to one in three patients will 
develop metastases depending on lymph node involvement 
and breast cancer subtype, despite remarkable progress in 
early diagnosis and treatment. A better understanding of prog-
nostic and predictive factors is allowing individualization of 
treatment for early stage breast cancer patients. The aim of 
these guidelines is to summarize current evidence and to give 
evidence-based recommendations for clinical practice [3].
Methodology
These SEOM Guidelines have been developed with the 
consensus of ten breast cancer medical oncologists from 
the cooperative groups GEICAM (Spanish Breast Cancer 
Research Group) and SOLTI (Spanish Collaborative Group 
for the Study, Treatment and Other Experimental Strate-
gies in Solid Tumors). To assign a level of evidence and 
a grade of recommendation to the different statements of 
this treatment guideline, it was decided to use the Infec-
tious Diseases Society of America-US Public Health Service 
Grading System for Ranking Recommendations in Clinical 
Guidelines to determine the quality of evidence and strength 
of recommendation in each of the consensus recommenda-
tions (Table 1). A full list of recommendations is provided 
in Table 2. 
Diagnosis and initial workup
The following tests allow a correct diagnosis and prognosis 
approach to all patients in whom the presence of a breast 
tumor is suspected.
– Bilateral mammography and ultrasound of the breast and 
regional lymph nodes [I, A] [4]. Several new techniques 
such as 3D mammography or 3D ultrasound can increase 
diagnostic accuracy but are not routinely implemented.
– Core needle biopsy (preferably by ultrasound or stereo-
tactic guidance). The study has to include the evaluation 
of the estrogen and progesterone receptor and HER2 gene 
expression [I, A]. Given the high inter-observer varia-
bility in the Ki-67 determination, it is important to be 
careful when using Ki67 to inform the decision-making 
process [5]. Fine needle aspiration or core biopsy of sus-
picious lymph nodes is recommended [II, A].
– MRI: is the most sensitive method for breast cancer stag-
ing but additional findings must be confirmed histologi-
cally due to the high false-positivity rate. Its use is not 
mandatory [I, B] and should be considered in cases of 
positive axillary nodes and occult primary breast cancer, 
Table 1  Strength of 




 A Good evidence to support a recommendation for use
 B Moderate evidence to support a recommendation for use
 C Poor evidence to support a recommendation
 D Moderate evidence to support a recommendation against use
 E Good evidence to support a recommendation against use
Quality of evidence
 I Evidence from ≥ 1 properly randomized, controlled trial
 II Evidence from ≥ 1 well-designed clinical trial, without rand-
omization; from cohort or case-controlled analytic studies 
(preferably from > 1 center); from multiple time series; or 
from dramatic results from uncontrolled experiments
 III Evidence from opinions of respected authorities, based 
on clinical experience, descriptive studies, or reports of 
expert committees
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Table 2  SEOM clinical practice guidelines for early breast cancer (2018 update): summary of recommendations
Recommendation Category, grade
Diagnosis and initial workup
 Bilateral mammography and ultrasound of breast and regional lymph nodes in patients with suspected breast cancer I, A
 Core needle biopsy including evaluation of estrogen and progesterone receptors together with HER2 expression in patients 
with suspected breast cancer
I, A
 Fine needle aspiration or core biopsy of suspicious lymph nodes II, A
 Bilateral breast MRI, with histologic confirmation of additional findings, as part of initial staging in patients with confirmed 
breast cancer, especially in patients with positive axillary nodes and occult primary breast cancer, Paget´s disease of the 
nipple, lobular carcinoma and multifocal or multicentric lesions
I, B
 Laboratory test as part of initial staging of patients with confirmed breast cancer III, B
 Additional staging with chest and abdomen CT and bone scan in patients with stage III disease and/or with clinical or labora-
tory suggesting metastases
III, B
 Additional staging with PET-CT in patients with locally advanced breast cancer II, A
 Evaluation of cardiac function in patients requiring anthracyclines and/or trastuzumab I, A
Surgery
 Consideration of breast-conserving surgery as first surgical option in stages I–II I, A
 No indication of additional excision in patients with no ink on invasive tumor or DCIS after breast-conserving surgery I, A
 Contralateral mastectomy should be offered through an appropriate counseling process in BRCA1/2 mutation carriers I, A
 Sentinel lymph node (SLN) biopsy in patients with clinically negative axillary nodes I, A
 Omission of axillary lymph node dissection in patients with stage I–II disease and less than three positive axillary nodes after 
SLN biopsy and lumpectomy followed by adjuvant systemic therapy and radiotherapy
I, A
 In patients with cN0 tumors, additional treatment of axilla is not necessary if SLNB is negative after neoadjuvant chemo-
therapy
I, A
 In patients with cN + tumors, if SLNB is negative after neoadjuvant chemotherapy (NAC):
  ALND should be considered the standard procedure I, A




 Hypofractionated schemes are preferred for external beam whole radiation therapy after breast-conserving surgery I, A
 In elderly patients, the benefit of radiotherapy after breast-conserving surgery for stage I tumors should be assessed individu-
ally
I, A
 Nodal (supra-and infra-clavicular) irradiation should be administered in patients with four or more involved nodes after 
breast-conserving surgery
I, A
 Nodal (supra-and infra-clavicular) irradiation is recommended in patients with one to three involved nodes after breast-
conserving surgery
I, B
 In cN0 patients with pT1-2 tumors and positive SLNB, axillary irradiation may be used as an alternative to ALND I, B
 Chest wall and regional node (supraclavicular and internal mammary) irradiation should be administered in patients with four 
or more involved nodes, T4 or T3N+ tumors after mastectomy
I, A
 Chest wall irradiation is recommended in patients with close or positive margins after mastectomy II, A
 Post-mastectomy irradiation should be considered in patients with T1-2 tumors and one to three involved nodes, or in patients 
with T3N0 tumors, after individually balancing risk factors for recurrence and patient preferences
I, B
 Adjuvant radiotherapy is recommended after NAC in patients with stage III and T3N0 disease, regardless of response to 
NAC, and in patients with node-positive disease after NACT 
I, A
 Adjuvant radiotherapy may be omitted after NAC in patients with stage II (excluding T3N0) who achieve a pCR and do not 
have additional risk factors for recurrence
I, B
Decision-making for systemic adjuvant treatment
 OncotypeDX recurrence score (RS) may be used for prediction of the risk of distant recurrence at 9 years in patients with 
hormone receptor (HR)-positive and HER2-negative breast cancer treated with adjuvant endocrine therapy-only
I, A
 OncotypeDX recurrence score (RS) may be used for prediction of the benefit of adjuvant chemotherapy in patients with 
hormone receptor (HR)-positive and HER2-negative
I, A
 Prosigna risk of distant recurrence score (ROR) may be used for prediction of the risk of distant recurrence at 10 years in 
patients with HR-positive and HER2-negative breast cancer treated with adjuvant endocrine therapy-only for 5 years
I, B
 Prosigna risk of distant recurrence score (ROR) may be used for prediction of the risk of late distant recurrence (years 5–10) 
in patients with HR-positive and HER2-negative breast cancer treated with adjuvant endocrine therapy-only for 5 years
I, B
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Table 2  (continued)
Recommendation Category, grade
 Mammaprint risk score may be used for prediction of the risk of distant recurrence at 5 years in patients with hormone recep-
tor (HR)-positive and HER2-negative breast cancer treated with adjuvant endocrine therapy-only
I, A
 EndoPredict Epclin score may be used for prediction of the risk of distant recurrence at 10 years in patients with HR-positive 
and HER2-negative breast cancer treated with adjuvant endocrine therapy-only for 5 years
I, B
 EndoPredict Epclin score may be used for prediction of the risk of late distant recurrence (years 5–10) in patients with HR-
positive and HER2-negative breast cancer treated with adjuvant endocrine therapy-only for 5 years
I, B
Adjuvant and neoadjuvant systemic treatment of luminal breast cancer
 Adjuvant endocrine therapy (ET) should be offered to any patient with HR-positive breast cancer I, A
 Adjuvant ET with tamoxifen for 5 years is recommended as a standard treatment for premenopausal women with HR-positive 
breast cancer
I, A
 Extended adjuvant ET with tamoxifen up to 10 years should be considered in high-risk patients I, B
 Adjuvant ET with exemestane plus ovarian function suppression should be offered to high-risk premenopausal breast cancer 
patients treated with adjuvant chemotherapy or in very young (under 35 years) women.
I, A
  In high-risk patients not suitable or intolerant to aromatase inhibitors, tamoxifen plus ovarian function suppression may be 
considered as an alternative
II, B
 Adjuvant ET for postmenopausal patients may consist in any of the following alternatives, after considering risk factors and 
individual preferences:
  Aromatase inhibitor (AI) during 5 years I, A
  Tamoxifen for 2–3 years followed by an AI to complete 5 years I, A
  Tamoxifen for 2–3 years followed by an AI during 5 years II, B
  Tamoxifen for 4.5–6 years followed by 2.5–5 years of an AI I, A
 Adjuvant treatment with oral or intravenous bisphosphonates should be considered in postmenopausal patients with breast 
cancer who are candidates for adjuvant systemic therapy
I, A
 Adjuvant chemotherapy with standard anthracyclines and/or taxane regimens for luminal breast cancer is recommended for 
tumors defined by either clinical or genomic risk factors: T2-4, axillary node involvement N2-3, extensive LVI, high Ki67, 
low ER expression, younger age and premenopausal status, and intermediate to high genomic score.
I, A
 NAC is indicated in locally advanced hormone receptor (HR)-positive and HER2-negative breast cancer I, A
 A sequential regimen of anthracyclines and taxanes is recommended in those patients in which NAC is indicated for hormone 
receptor (HR)-positive and HER2-negative breast cancer
II, B
 Aromatase inhibitors are preferred over tamoxifen in postmenopausal patients in which neoadjuvant endocrine therapy is 
indicated for hormone receptor (HR)-positive and HER2-negative breast cancer
I, A
 Neoadjuvant endocrine therapy with AI plus ovarian suppression or with tamoxifen might be considered in selected premeno-
pausal patients in which chemotherapy is not an option
II, D
Adjuvant and neoadjuvant systemic treatment of HER2 breast cancer
 Addition of adjuvant trastuzumab to chemotherapy is recommended for HER2-positive breast cancer both in node-positive 
and in node-negative tumors with a tumor size > 1 cm
I, A
  12-month duration of trastuzumab should be considered standard I, A
 Addition of adjuvant trastuzumab to chemotherapy should be considered in most cases of node-negative HER2-positive 
breast cancer with tumor size of 0.5–1.0 cm
II, B
 For adjuvant chemotherapy of HER2-positive breast cancer, AC or EC for 4 cycles followed by 3 months of paclitaxel (P) or 
docetaxel (D or T) both in combination with trastuzumab (AC/EC → P/D + H) or docetaxel, carboplatin and trastuzumab 
(TCH) are the preferred regimens
I, A
  In node-negative stage I tumors, an alternative less intense regimen with single-agent paclitaxel and trastuzumab for 
12 weeks followed by single-agent trastuzumab (to complete a year) may be considered
II, B
 Adjuvant dual HER2 blockade with trastuzumab and Pertuzumab for 18 cycles may be considered in patients with high-risk 
(node-positive and/or HR-negative) HER2-positive breast cancer. In patients that have received neoadjuvant treatment, 
Pertuzumab may be continued after surgery up to 18 cycles
I, B
 Extended adjuvant treatment with neratinib after one year of trastuzumab may be considered in patients with node-positive 
and HR-positive HER2-positive breast cancer
I, B
 Dual blockade with trastuzumab and pertuzumab and chemotherapy should be considered for the treatment of HER2-positive 
breast cancer patients who meet criteria for neoadjuvant treatment (> 2 cm tumor size and/or node-positive)
II, B
Adjuvant and neoadjuvant systemic treatment of triple-negative breast cancer
 Adjuvant chemotherapy for triple-negative breast cancer should include an anthracycline and a taxane, although the regimen 
docetaxel-cyclophosphamide might be considered in patients with a high risk for cardiac toxicity
I, B
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Paget´s disease of the nipple, lobular carcinoma and mul-
tifocal or multicentric lesions. It is recommended prior 
and after neoadjuvant treatment to define the extent of 
disease and monitor the response to treatment [III, A] [6].
– Additional studies: anamnesis with personal and fam-
ily medical history and complete physical examination. 
Lab test (complete blood count, liver and renal function, 
alkaline phosphatase and calcium) are routinely used but 
do not seem to improve detection of occult metastatic 
disease [III, B] [7].
When disease is detected in stage III or when signs or 
symptoms or laboratory values suggest suspected metasta-
sis, a more extensive study with thoracic CT, abdominal 
CT and bone scan [III, B] should be performed. PET/CT 
is also recommended for initial staging in locally advanced 
BC (LABC) [II, A] [8].
Evaluation of cardiac function is imperative when using 
anthracyclines or trastuzumab [I, A] [9].
Principles of surgery
Breast-conserving surgery is equivalent to mastectomy and 
must be considered as first option in most cases of stages I–II 
(I, A) [10]. No ink on invasive tumor or DCIS is considered 
an adequate margin after breast-conserving surgery [I, A] 
[11]. Mastectomy is still indicated in the following situa-
tions: tumor multicentricity, inability to achieve negative 
surgical margins after multiple resections, small breast size 
according to tumor volume, prior radiation therapy in the 
breast, or other contraindications for radiotherapy.
When mastectomy is performed, contralateral mastec-
tomy as a prophylactic procedure is not indicated in most 
of the patients [12]. However, for carriers of BRCA1/2 
mutations, the contralateral mastectomy should be offered 
through an appropriate risk–benefit assessment and coun-
seling process [I, A] [13].
Sentinel lymph node biopsy (SLNB) is recommended 
for assessment of the involvement of axillary lymph nodes 
and should be performed in patients with clinically nega-
tive axillary nodes [I, A]. In patients with clinically positive 
axillary nodes, pathologic confirmation must be done by 
ultrasonography-guided fine needle aspiration (FNA) or core 
biopsy. Axillary lymph node dissection (ALND) is indicated 
in patients with positive SLN biopsy or confirmed preopera-
tive pathologic axillary lymph node involvement. However, 
in patients with stage I-II disease and less than three positive 
axillary nodes after SLN biopsy and lumpectomy (and adju-
vant radiotherapy indicated), ALND can be avoided without 
significant negative impact in DFS and OS when an adequate 
systemic postoperative treatment is provided [I, A] [14].
SLNB may be offered in patients with operable breast 
cancer before or after neoadjuvant chemotherapy (NACT). 
In patients with cN0 axilla, additional axillary treatment is 
not necessary if SLNB is negative after NACT [I, A] [15]. 
In patients with cN+ axilla who achieved ycN0 status after 
NACT, the ALND is recommended as standard procedure 
due to the high false-negative rate of the SLNB [I, A] [16]. 
In selected cN+ cases, in which positive axillary node has 
been marked prior to NACT, the identification and recovery 
of > 2 SLNs (including the marked node) with a double-
contrast technique (Tc99 and methylene blue) may avoid 
ALND [II, C].
Table 2  (continued)
Recommendation Category, grade
 No adjuvant chemotherapy is recommended for node-negative pT1a triple-negative breast cancer III, B
 Adjuvant chemotherapy may be considered for 0.6–1 cm tumors after an adequate individualized balance III, B
 Neoadjuvant chemotherapy for triple-negative breast cancer should include sequential anthracyclines and taxanes I, A
 Carboplatin may be considered as part of neoadjuvant chemotherapy for triple-negative breast cancer patients I, A
 Adjuvant capecitabine for 6-8 cycles should be considered in high-risk triple-negative breast cancer with residual invasive 
disease at surgery following standard neoadjuvant chemotherapy
I, B
Follow-up of early breast cancer
 Breast cancer surveillance is recommended in order to detect breast cancer recurrence and second primary tumors, assess 
physical and psychosocial long-term effects of breast cancer and its treatment, and promote a healthy lifestyle
I, A
 Healthy lifestyles are recommended to prevent tumor recurrence II, A
 Early breast cancer follow-up should include regular visits every 3–6 months in the first 2 years, every 6 months from years 
3–5 and annually thereafter
III, A
 Annual ipsilateral (after breast-conserving surgery) and/or a contralateral mammography with ultrasound is recommended for 
follow-up of early breast cancer
II, A
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Recommendations of adjuvant radiotherapy
Adjuvant radiotherapy (RT) should be performed in the case of:
– Breast-conserving surgery: external beam whole radiation 
therapy (WBRT). Hypofractionation schemes are preferred 
[I, A] [17]. If four or more nodes are involved, supra and 
infraclavicular radiotherapy is recommended [I, A]. In 
patients with one to three involved nodes after breast-con-
serving surgery, supra and infraclavicular nodal irradiation 
is recommended to minimize the risk of recurrence and 
potentially improve disease-specific survival [I, B] [18]. In 
addition, in patients with T1-2 tumors and cN0 and sentinel 
lymph node metastases, axillary irradiation is an alternative 
comparable to the ALND with less morbidity [I, B] [19].
– Mastectomy: chest wall and regional node irradiation 
including supraclavicular and internal mammary region is 
recommended in T4 tumors, node-positive T3 tumors, and 
if involvement of ≥ 4 axillary lymph nodes [I, A]. In cases of 
close or positive margins, chest wall irradiation is also rec-
ommended [II, A] [18, 20]. T1-2 tumors with one to three 
involved nodes and T3N0 tumors have an increased risk of 
locoregional recurrence after mastectomy. Post-mastectomy 
RT reduces the risk of recurrence and mortality and should 
be considered in these patients. However, benefit of adjuvant 
RT can be small in some subgroups of patients and must be 
discussed based on other risk factors such as grade, age, 
lymphovascular invasion, receptor status or lack of systemic 
therapy [I, B] [18, 21]. After neoadjuvant chemotherapy 
(NAC), irradiation is recommended for stage III disease, 
regardless of response to NAC, and for node-positive dis-
ease after NAC [I, A]. For patients presenting with stage II 
disease (excluding cT3N0) who achieve a pathologic com-
plete response (pCR), radiotherapy could be omitted unless 
other risk factors [I, B]. [21–23].
Despite these recommendations, benefit of RT for stage I 
elderly patients has not been proved and should, therefore, be 
assessed individually [I, A] [24]. Some low-risk patients treated 
with conservative surgery could be spared whole breast RT 
and receive partial breast radiation or intraoperative treatment, 
although less evidence exists to support this approach [25].
Principles of adjuvant systemic therapy. 
Genomic profiles in decision making 
in systemic adjuvant treatment
Principles of adjuvant systemic therapy
Breast cancer (BC) is a heterogeneous disease, with different 
subtypes having a distinct biological, molecular, and clinical 
outcome. Systemic adjuvant treatment is commonly used in 
early breast cancer with the intention to reduce the rate of 
locoregional or systemic relapses and death derived from 
the disease. Treatment decisions are based on clinical (age, 
comorbidities) and pathologic factors (tumor size, nodal sta-
tus, grade, hormone receptor (HR) status and HER2 status). 
Multigenic tests provide information beyond standard clini-
cal and pathologic prognostic factors that can help in making 
treatment decisions.
Prognostic gene expression‑based assays
Several prognostic gene expression-based assays have been 
developed to personalize the decision regarding the addition 
of chemotherapy (CT) in hormone receptor (HR)-positive 
and HER2-negative BC [26–30].
Oncotype DX
The test was initially validated as a prognostic biomarker 
in tumor samples from several prospective clinical trials 
(e.g., NSABP-B14 and TransATAC) [30–35]. A score cut-
point of  less than 18 identified low-risk patients at 10 years 
that could be spared multi-agent chemotherapy, specially in 
node-negative disease. Less clear was the need of adjuvant 
chemotherapy in patients with a score of 18 to 31. TAI-
LORx prospective trial in HR+/HER2−/node-negative dis-
ease reported that in the intermediate risk group, defined 
as 11–25, no benefit of adding chemotherapy to endocrine 
therapy was observed in the overall population at 9 years, 
although some benefit of chemotherapy was found in 
women ≤ 50 years of age [29]. An important point is that 
the vast majority of patients (74%) recruited in TAILORx 
were clinically low risk (i.e., 63% had tumor sizes 1–2 cm). 
Indeed, no clear differences in survival outcomes were 
observed between the intermediate groups (with or without 
chemotherapy) compared to the low-risk group (i.e., < 11). 
The RxPONDER prospective clinical trial in 1–3 positive 
nodes and RS < 25 will shed more light regarding the ability 
of OncotypeDX RS to predict chemotherapy benefit. Level 
of evidence: IA for the prediction of adjuvant chemother-
apy benefit in patients with clinically low-risk disease and a 
recurrence score 11–25; IA for the prediction of the risk of 
distant recurrence at 9 years if treated with adjuvant endo-
crine therapy-only.
Prosigna
This assay classifies a tumor to one of the 4 intrinsic subtypes 
(Luminal A, Luminal B, HER2-enriched and basal-like) and 
provides a prognostic 10-year Risk of distant Recurrence 
(ROR) score [36], which integrates genomic data together 
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with tumor size and nodal status (to determine the risk cut-
offs). ROR has now been validated retrospectively in node-
negative and node-positive disease in tumor samples from 
several large adjuvant studies (i.e., TransATAC, ABCSG-08 
and Danish cohort) [37–41]. In a recent head-to-head com-
parison with OncotypeDX RS and EndoPredict in 774 tumor 
samples from TransATAC, ROR provided a more accurate 
long-term prognostic information than OncotypeDX, similar 
to EndoPredict [41, 42]. Prospective validation of the abil-
ity of Prosigna to predict adjuvant chemotherapy survival 
benefit is currently ongoing in large phase III trial in UK 
(i.e., the OPTIMA trial), in patients ≥ 40 years of age with 
HR+/HER2−, > 3 cm or node-positive tumors and an ROR 
below 60 (i.e., low/intermediate). A recent published trial 
showed the prognostic and predictive value of Prosigna in 
premenopausal high-risk breast cancer patients treated with 
cyclophosphamide-based adjuvant chemotherapy [43]. Level 
of evidence: IB for the prediction of the risk of distant recur-
rence at 10 years if treated with 5 years of adjuvant endo-
crine therapy-only; Level of evidence: IB for the prediction 
of late distant recurrence (years 5–10) if treated with 5 years 
of adjuvant endocrine therapy-only.
Mammaprint
The prognostic value of Mammaprint was first validated in 
295 patients with pT1 or pT2 tumors with node-negative or 
node-positive disease [26, 27]. Since then, other retrospec-
tive validations of its prognostic value have been reported. 
Recently, the primary results of the prospective prognostic 
validation of Mammaprint have been reported. The MIN-
DACT trial was an international phase III trial designed to 
evaluate the 5-year distant relapse-free survival (DRFS) in 
748 patients, largely HR+/HER2-negative, with a genomic 
low-risk score and a clinically high-risk score (defined 
by a modified version of AdjuvantOnline!) when treated 
without adjuvant chemotherapy. The study met its primary 
endpoint and this group of patients had a 5-year DRFS of 
94.7% (92.5–96.2). However, longer follow-up is needed to 
determine if this group of patients continues to have an out-
standing outcome after 5 years in order to spare them from 
adjuvant chemotherapy [44]. As a secondary underpowered 
analysis of the MINDACT trial, Mammaprint did not dem-
onstrate the ability to predict chemotherapy survival benefit. 
Level of evidence: IA for the prediction of the risk of dis-
tant recurrence at 5 years if treated with adjuvant endocrine 
therapy-only.
EndoPredict
The prognostic value of EPclin has been validated retro-
spectively in tumors samples from 3 large phase III trials 
(ABCSG-6/ABCSG-8 [45] and TransATAC [46]), where 
patients did not receive any adjuvant chemotherapy. In addi-
tion, the assay has shown ability to predict late distant recur-
rence [46, 47]. Level of evidence: IB for the prediction of the 
risk of distant recurrence at 10 years if treated with 5 years 
of adjuvant endocrine therapy-only. Level of evidence: IB 
for the prediction of late distant recurrence (years 5 to 10) 
if treated with 5 years of adjuvant endocrine therapy-only.
Systemic treatment for luminal‑type early 
stage breast cancer
Adjuvant endocrine therapy for early stage breast 
cancer
There is robust evidence that endocrine therapy (ET) 
improves survival of early stage luminal breast cancer 
(BC). Adjuvant ET should be offered to any of these patients 
regardless of age, menopausal status, chemotherapy expo-
sure, expression level of ER or PgR (if any or both are posi-
tive defined as ER and/or PR > 1%), and/or Her2 status [I, 
A]. There are several ET options. The individual choice 
would be adjusted to menopause status, comorbidity, and 
the risk of recurrence.
Tamoxifen is the most established adjuvant ET for both 
premenopausal and postmenopausal women as it reduces the 
risk of recurrence by 40% in all subgroups [48]. Two large 
trials (ATLAS and aTTom trial) concluded a higher benefit 
of continuing Tamoxifen until 10 years, which is recom-
mended for high-risk tumors (at the cost of greater toxicity) 
[I, B] [49, 50].
Five years of tamoxifen remain the standard treatment 
for premenopausal women [I, A] [51], but other alterna-
tives should be considered. Adjuvant exemestane plus ovar-
ian function suppression as compared with tamoxifen plus 
ovarian function suppression or tamoxifen alone signifi-
cantly reduced the likelihood of distant recurrence in high-
risk adjuvant chemotherapy-treated premenopausal breast 
cancer patients [I, A]. After a median follow-up of 8 years, 
a survival improvement favoring ovarian suppression plus 
tamoxifen has been shown [52]. EBCTCG and SOFT trials 
also support adjuvant tamoxifen plus GnRH analogs as an 
alternative for high-risk patients not suitable to aromatase 
inhibitors [II, B] [53].
Several studies explored aromatase inhibitors (AIs) as 
an initial therapy [54–56], as sequential therapy following 
2–3 years of tamoxifen [55–59] or as extended therapy [60, 
61] for postmenopausal patients. Different options can be 
recommended: an AI for 5 years [I, A], tamoxifen for 2 to 
3 years followed by an AI to complete 5 years [I, A] or dur-
ing 5 years [II, B], or tamoxifen for 4.5 to 6 years followed 
by 2.5 to 5 years of an AI [I, A]. The recently published 
IDEAL trial did not find differences between 2.5 or 5 years 
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of an AI after 5 years of any ET [62]. The option of 10 years 
of tamoxifen could be considered in patients with contrain-
dication to AIs or who remain premenopausal.
There is strong evidence to consider the use of bis-
phosphonates (zoledronic acid 4 mg intravenously every 
6 months or clodronate 1.600 mg/d orally) but not an anti-
RANK-ligand antibody as additional adjuvant therapy for 
postmenopausal patients with breast cancer who are candi-
dates for adjuvant systemic therapy. [I, A] [63].
Adjuvant chemotherapy in hormone 
receptor‑positive early BC
The use of chemotherapy as adjuvant treatment for 
ER+ Her2-negative disease is recommended for high-risk 
tumors defined by either clinical or genomic profiling char-
acteristics [I, A], considering: T2 to T4 tumors and/or axil-
lary N2-3 involvement; extensive LVI, high KI67, low ER 
expression, younger age or premenopausal status; and inter-
mediate to high genomic score. Standard anthracycline and 
taxane regimens are recommended [90] [I, A].
Neoadjuvant chemotherapy for luminal breast 
cancer
Neoadjuvant CT is indicated in LABC [I, A] to reduce the 
extent of surgery, to treat micrometastases promptly and to 
monitor the response.
All treatments recommended in the adjuvant setting may 
also be used in the preoperative setting. If chemotherapy is 
used, it should be delivered before surgery, without breaks, 
with the aim to increase the rate of breast-conserving sur-
gery (pCR are infrequent in this setting). A sequential 
regimen of anthracyclines and taxanes is associated with 
increased probability of pCR and must be recommended [II, 
B] [64, 65]. In selected cases of postmenopausal patients 
with ER+/Her2− disease, neoadjuvant endocrine therapy 
(NET) during at least 16 weeks is a good option. The avail-
able data directly comparing neoadjuvant endocrine therapy 
(NET) with neoadjuvant chemotherapy are very limited. 
Some phase II trials and one meta-analysis showed similar 
response rates, but a significantly lower toxicity with NET 
[66]. AIs are better to tamoxifen as NET [I, A] [67]. The 
efficacy evaluation of NET has been performed according to 
surrogate parameters such as the decrease of the Ki67 levels 
or the preoperative endocrine prognostic index (PEPI) score 
[68]. Neoadjuvant ET in premenopausal patients is debat-
able; an AI with ovarian suppression or tamoxifen could be 
considered in selected cases in which chemotherapy is not 
an option [II, D].
In the neoadjuvant setting, chemotherapy is an accepted 
treatment for tumors with node metastases and for tumors 
greater than 2 cm who are candidates to mastectomy. We 
use clinical and pathologic parameters (HR status, grade, 
Ki-67) to select patients for neoadjuvant chemotherapy 
(NCT), though there is no agreement about the cutoff point 
of Ki-67 and about the accuracy of this marker to predict 
chemotherapy response. Different genetic signatures have 
been evaluated in core needle biopsy before neoadjuvant 
therapy, as good predictors of response to neoadjuvant 
therapy, especially PAM50 ROR score [69], although this 
approach is currently considered experimental.
Systemic treatment for early stage 
her2‑positive breast cancer
Adjuvant treatment for HER2‑positive disease 
[70–77]
The addition of trastuzumab to chemotherapy has dramati-
cally improved prognosis for early stage HER2-positive 
breast cancer patients. The benefits of trastuzumab are 
independent of age, tumor size, nodal and HR status. Adju-
vant trastuzumab is recommended in node-positive and 
node-negative tumors with a tumor size > 1 cm [I, A]. No 
level I evidence exists regarding the use of trastuzumab in 
node-negative and tumors ≤ 1 cm, although it might be con-
sidered in most patients with tumor size 0.5–1.0 cm [II, B]. 
While trastuzumab added sequentially after chemotherapy 
has demonstrated activity, results from the NCCTG N9831 
study and a meta-analysis suggest better outcomes when 
trastuzumab is given concurrently with taxane-based treat-
ment. Thus, AC or EC for 4 cycles followed by 3 months of 
paclitaxel (P) or docetaxel (D or T) both in combination with 
trastuzumab (AC/EC → P/D + H) or docetaxel, carboplatin 
and trastuzumab (TCH) are preferred regimens [I, A]. It is 
important to consider cardiac risk factors when determin-
ing the appropriate chemotherapy backbone to administer 
with trastuzumab. In small, node-negative tumors (stage-
I), although not all patients require adjuvant trastuzumab-
based chemotherapy (particularly those with pT1aN0), a 
less intense chemotherapy regimen such as single-agent 
paclitaxel and trastuzumab for 12 weeks followed by single-
agent trastuzumab to complete one year provides excellent 
outcomes [II, B]. To date, 12-month duration of trastuzumab 
remains the standard of care in most situations [I, A]. How-
ever, in patients with cardiac toxicity or at very high risk of 
cardiac toxicity, a shorter course (i.e., 6 months duration) 
can be considered. Trastuzumab may also be safely com-
bined with either radiotherapy or endocrine therapy.
While there have been many efforts to improve out-
comes even further, the addition of novel anti-HER2 thera-
pies to trastuzumab, such as pertuzumab or neratinib, has 
led to significant, but modest improvements in DFS, and no 
impact on OS has yet been reported. Balancing risks and 
Clinical and Translational Oncology 
1 3
benefits is critical when evaluating adjuvant dual block-
ade with pertuzumab plus trastuzumab or extended HER2 
inhibition with neratinib following 1-year of trastuzumab. 
Up to 18 cycles of adjuvant pertuzumab in combination 
with trastuzumab-based chemotherapy showed a 19% 
relative reduction in invasive disease-free survival (iDFS) 
at 3 years in the large phase III APHINITY trial. When 
stratification factors were evaluated, patients with high-
risk features such as node positive or HR negative derived 
a significant iDFS, whereas patients with node negative or 
HR+ disease did not. Although longer follow-up is needed, 
EMA states that the available data do not allow concluding 
for a positive benefit-risk ratio in the overall population. 
However, EMA considers that benefit is clearly shown in 
the high-risk population (HR-negative or node-positive) 
[I, B] for a total duration of 18 cycles of dual blockade, 
regardless if it was initiated in the adjuvant or the neoad-
juvant setting.
The addition of 1 year of adjuvant neratinib improved 
iDFS in patients with HER2-positive early breast cancer 
after 1 year of trastuzumab, as demonstrated in the phase III 
EXTENET trial. However, the benefit was higher in patients 
with HR-positive and node-positive disease, at the expense 
of increased diarrhea [I, B]. Recently, neratinib has been 
approved by EMA, which restricted its use to HR+ disease. 
However, there are no data on the added benefit of neratinib 
in patients who also received pertuzumab.
Neoadjuvant treatment for HER2‑positive disease 
[78–81]
In the neoadjuvant setting, trastuzumab in combination 
with chemotherapy (taxane and anthracycline based) has 
been the standard treatment for HER2-positive tumors with 
nodal involvement or tumor size > 2 cm. Two phase II trials 
evaluated the addition of pertuzumab to trastuzumab-based 
chemotherapy, demonstrating higher rates of pCR. These 
data, along with its efficacy in terms of OS in the metastatic 
setting, led to the accelerated approval of this combination 
in the neoadjuvant scenario. Dual blockade with trastu-
zumab and pertuzumab and chemotherapy (anthracycline 
plus taxane based, or anthracycline-free regimens) should 
be considered for the treatment of HER2-positive breast 
cancer patients who meet criteria for neoadjuvant treatment 
(i.e., > 2 cm tumor size or node positive). According to EMA 
and FDA, treatment with dual HER2 blockade can be con-
tinued after surgery for up to 18 cycles [I, B]. At this point, 
the type of pathological response at surgery should not guide 
the duration of trastuzumab or pertuzumab since there are 
no data supporting one strategy or another. Finally, the addi-
tion of lapatinib to trastuzumab and chemotherapy has not 
consistently improved pCR rates and long-term outcome. 
To date, this combination cannot be recommended for the 
treatment of patients with early stage HER2-positive breast 
cancer [I,E].
Systemic therapy for early stage 
triple‑negative breast cancer
Adjuvant treatment for triple‑negative disease
Triple-negative breast cancer (TNBC) is a heterogeneous 
disease comprising approximately 15% of all breast cancers. 
With the exception of medullary, adenoid cystic, and apo-
crine carcinomas that have a better outcome, TNBCs have 
generally an aggressive behavior.
Conventional chemotherapy remains the mainstay of 
adjuvant systemic treatment for most patients with early 
TNBC. Adjuvant chemotherapy should include an anthra-
cycline and a taxane [I, B], although the regimen docetaxel-
cyclophosphamide might be considered in patients with a 
high risk for cardiac toxicity. Nevertheless, women with 
T1a/bN0 tumors have an excellent prognosis without chemo-
therapy [82]. No adjuvant chemotherapy is recommended in 
tumors equal or less than 0.5 cm (pT1a), and for 0.6–1 cm 
tumors, it has to be discussed and balanced [III, B]. No 
robust, prospective randomised data exist on the use of plati-
num compounds in the adjuvant setting, either in unselected 
triple-negative tumors or BRCA 1/2 mutation carriers.
Neoadjuvant treatment for triple‑negative disease
Neoadjuvant therapy in TNBC leads to pCR rates of 
30–40%, which has been associated with an excellent prog-
nosis [65]. It is recommended that a sequential regimen of 
anthracyclines and taxanes is used for the vast majority of 
patients [I, B]. An improved pCR was observed with Nab-
paclitaxel compared to solvent-based weekly paclitaxel (43 
vs 34%) in a head to head phase III neoadjuvant trial. This 
effect was seen in all subgroups, especially in TNBC patients 
[83].
Platinum-based neoadjuvant chemotherapy significantly 
increased pCR from 37.0% to 52.1% (OR 1.96, 95% CI 
1.46–2.62, P < 0.001), with significant higher risk of grade 
3 and 4 hematological AEs [I, A]. In the 96 BRCA-mutated 
patients included in two randomized controlled trials, the 
addition of carboplatin was not associated with significantly 
increased pCR rate [84]. The effect of those compounds on 
long-term outcomes is unknown [I, B].
Addition of 6–8 cycles of adjuvant capecitabine therapy 
among patients who had residual invasive disease on patho-
logical testing after anthracycline and taxane-based neoadju-
vant chemotherapy was safe and effective in prolonging DFS 
and OS in the randomized phase III CREATE-X trial [85]. 
Based on those results and a meta-analysis [86], adjuvant 
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capecitabine can be considered in high-risk TNBC patients 
with residual invasive disease at surgery following standard 
neoadjuvant chemotherapy [I, B] This treatment, though, 
must be balanced against potential toxicities.
Recommendation: sequential regimens of anthracyclines 
followed by taxanes are the standard treatment. Platinum-
based neoadjuvant chemotherapy may be considered an 
option in TNBC patients [I, A].
Follow‑up
Follow-up after surgery and adjuvant treatment of breast 
cancer patients is widely reported in guidelines worldwide. 
Surveillance for breast cancer recurrence, screening for sec-
ond primary cancers, assessment and management of physi-
cal and psychosocial long-term and late effects of breast 
cancer and its treatment, and health promotion are encour-
agingly recommended [I, A] [87]. Healthy lifestyles, such 
as physical exercise and avoidance of obesity, are recom-
mended to prevent tumor recurrence [II, A] [88].
Despite the fact that no randomized data exist to support 
any particular follow-up sequence or protocol, balancing 
patient needs and follow-up costs, we recommend regular 
visits every 3–6 months in the first 2 years, every 6 months 
from years 3–5 and annually thereafter [III, A]. Every visit 
should include a thorough history, eliciting of symptoms and 
a physical examination. Annual ipsilateral (after BCT) and/
or a contralateral mammography with ultrasound is recom-
mended [II, A]. An MRI of the breast may be indicated for 
young patients, especially in cases of dense breast tissue and 
genetic or familial predispositions [89].
Compliance with ethical standards 
Conflict of interest FAP reports grants from Roche and Celgene, 
other from Roche, Celgene, Eisai, AstraZeneca, Pfizer, Pierre Fabre 
and Novartis, outside the submitted work. RA has nothing to disclose. 
JAGS reports personal fees from Novartis and Celgene, grants from As-
traZeneca, other from Roche, outside the submitted work. LM reports 
other from Roche, other from AstraZeneca, other from Novartis, other 
from Tesaro, outside the submitted work. MM has received speaker 
honoraria  and funding for some independent medical education ac-
tivities from Roche, Novartis, Astra Zeneca, Kern and Merck outside 
the submitted work. ED has nothing to disclose. SP reports personal 
fees and non-financial support from Roche, other from Polyphor, non-
financial support from Pierre Fabre, outside the submitted work. AP 
reports personal fees from Nanostring, Roche, Amgen, Novartis, Eli 
Lilly and Pfizer, and grants from Roche, Novartis and Nanostring, all 
outside the submitted work. AP is part of the scientific advisory board 
of Oncolytics Biotech. SS has nothing to disclose. EC reports personal 
fees and other from Roche, Pfizer, Novartis, MSD, Celgene, Lilly and 
Pierre Fabre, outside the submitted work.
Ethical standards The current study has been performed in accordance 
with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments. This article does not contain any studies 
with human participants or animals performed by any of the authors.
Informed consent For this type of study, no informed consent is 
required.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. SEOM: Las Cifras Del Cáncer En España. 2018. https ://seom.
org/seomc ms/image s/stori es/recur sos/Las_Cifra s_del_cance 
r_en_Espan a2018 .pdf. Accessed 15 Oct 2018.
 2. Cho S-H, Jeon J, Kim SI. Personalized medicine in breast can-
cer: a systematic review. J Breast Cancer. 2012;15:265–72.
 3. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. 
Comparisons between different polychemotherapy regimens 
for early breast cancer: meta-analyses of long-term outcome 
among 100,000 women in 123 randomised trials. Lancet. 
2012;379:432–44.
 4. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von 
Karsa L. European guidelines for quality assurance in breast 
cancer screening and diagnosis. Fourth edition–summary docu-
ment. Ann Oncol. 2007;19:614–22.
 5. Polley YC, Leung SCY, McShane LM, Gao D, Hugh JC, 
Mastropasqua MG, et al. International Ki67 in Breast Cancer 
Working Group of the Breast International Group and North 
American Breast Cancer Group. An International Ki67 Repro-
ducibility Study. J Natl Cancer Inst. 2013;105:1897–906.
 6. Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gil-
bert FJ, et al. Magnetic resonance imaging of the breast: recom-
mendations from the EUSOMA working group. Eur J Cancer. 
2010;46:1296–316.
 7. Louie RJ, Tonneson JE, Gowarty M, Goodney PP, Barth RJ, 
Rosenkranz KM. Complete blood counts, liver function tests, 
and chest x-rays as routine screening in early-stage breast 
cancer: value added or just cost? Breast Cancer Res Treat. 
2015;154:99–103.
 8. Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S, 
Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, et al. 
Oncology Task Force of the Spanish Society of Nuclear Medi-
cine and Molecular Imaging: 18F-FDG PET/CT in breast can-
cer: evidence-based recommendations in initial staging. Tumour 
Biol. 2017;39:1010428317728285.
 9. López-Fernández T, Martín García A, Santaballa Beltrán A, 
Montero Luis Á, García Sanz R, Mazón Ramos P, et al. Car-
dio-Onco-Hematología en la práctica clínica. Documento de con-
senso y recomendaciones. Rev Española Cardiol. 2017;70:474–86.
 10. Association of Breast Surgery at Baso 2009. Surgical guide-
lines for the management of breast cancer. Eur J Surg Oncol. 
2009;35(Suppl 1):1–22.
 11. Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond 
MEH, Lyman GH, et al. Margins for breast-conserving surgery 
with whole-breast irradiation in Stage I and II invasive breast 
cancer: American Society of Clinical Oncology Endorsement of 
the Society of Surgical Oncology/American Society for Radiation 
Oncology Consensus Guideline. J Clin Oncol. 2014;32:1502–6.
Clinical and Translational Oncology 
1 3
 12. Fayanju OM, Stoll CRT, Fowler S, Colditz GA, Margenthaler 
JA. Contralateral prophylactic mastectomy after unilateral 
breast cancer. Ann Surg. 2014;260:1000–10.
 13. Li X, You R, Wang X, Liu C, Xu Z, Zhou J, et al. Effectiveness 
of prophylactic surgeries in BRCA1 or BRCA2 mutation car-
riers: a meta-analysis and systematic review. Clin Cancer Res. 
2016;22:3971–81.
 14. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumen-
cranz P, Leitch AM, et al. Locoregional recurrence after sentinel 
lymph node dissection with or without axillary dissection in 
patients with sentinel lymph node metastases. Trans Meet Am 
Surg Assoc. 2010;128:12–21.
 15. van der Heiden-van der Loo M, de Munck L, Sonke GS, van 
Dalen T, van Diest PJ, van den Bongard HJGD, et al. Population 
based study on sentinel node biopsy before or after neoadjuvant 
chemotherapy in clinically node negative breast cancer patients: 
identification rate and influence on axillary treatment. Eur J 
Cancer. 2015;51:915–21.
 16. van Nijnatten TJA, Schipper RJ, Lobbes MBI, Nelemans PJ, 
Beets-Tan RGH, Smidt ML. The diagnostic performance of 
sentinel lymph node biopsy in pathologically confirmed node 
positive breast cancer patients after neoadjuvant systemic ther-
apy: a systematic review and meta-analysis. Eur J Surg Oncol. 
2015;41:1278–87.
 17. Whelan TJ, Pignol J-P, Levine MN, Julian JA, MacKenzie R, 
Parpia S, et al. Long-term results of hypofractionated radiation 
therapy for breast cancer. N Engl J Med. 2010;362:513–20.
 18. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), 
McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect 
of radiotherapy after mastectomy and axillary surgery on 10-year 
recurrence and 20-year breast cancer mortality: meta-analysis of 
individual patient data for 8135 women in 22 randomised trials. 
Lancet. 2014;83:212–35.
 19. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde 
CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after 
a positive sentinel node in breast cancer (EORTC 10981-22023 
AMAROS): a randomised, multicentre, open-label, phase 3 non-
inferiority trial. Lancet Oncol. 2014;15:1303–10.
 20. Jagsi R, Raad RA, Goldberg S, Sullivan T, Michaelson J, Powell 
SN, et al. Locoregional recurrence rates and prognostic factors 
for failure in node-negative patients treated with mastectomy: 
implications for postmastectomy radiation. Int J Radiat Oncol. 
2005;62:1035–9.
 21. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka 
EK, et al. Locoregional recurrence risk for patients With T1,2 
breast cancer with 1–3 positive lymph nodes treated with mastec-
tomy and systemic treatment. Int J Radiat Oncol. 2014;89:392–8.
 22. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, 
Buzdar AU, et  al. Postmastectomy radiation improves local-
regional control and survival for selected patients with locally 
advanced breast cancer treated with neoadjuvant chemotherapy 
and mastectomy. J Clin Oncol. 2004;22:4691–9.
 23. Nagar H, Mittendorf EA, Strom EA, Perkins GH, Oh JL, Ter-
effe W, et al. Local-regional recurrence with and without radia-
tion therapy after neoadjuvant chemotherapy and mastectomy 
for clinically staged T3N0 breast cancer. Int J Radiat Oncol. 
2011;81:782–7.
 24. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry 
DA, McCormick B, et al. Lumpectomy plus tamoxifen with or 
without irradiation in women age 70 years or older with early 
breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 
2013;31:2382–7.
 25. Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, 
Thompson AM, et  al. Accelerated partial breast irradiation: 
executive summary for the update of an ASTRO evidence-based 
consensus statement. Pract Radiat Oncol. 2016;7:73–9.
 26. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A 
multigene assay to predict recurrence of tamoxifen-treated, node-
negative breast cancer. N Engl J Med. 2004;351:2817–26.
 27. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene 
expression and benefit of chemotherapy in women with node-
negative, estrogen receptor-positive breast cancer. J Clin Oncol. 
2006;24:3726–34.
 28. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, 
Hayes DF, et al. Prospective validation of a 21-gene expression 
assay in breast cancer. N Engl J Med. 2015;373:2005–14.
 29. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain 
KS, Hayes DF, et  al. Adjuvant chemotherapy guided by a 
21-gene expression assay in breast cancer. N Engl J Med. 
2018;379:111–21.
 30. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, 
Yeh I-T, et al. Prognostic and predictive value of the 21-gene 
recurrence score assay in postmenopausal women with node-
positive, oestrogen-receptor-positive breast cancer on chemo-
therapy: a retrospective analysis of a randomised trial. Lancet 
Oncol. 2010;11:55–65.
 31. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. 
Prediction of risk of distant recurrence using the 21-gene recur-
rence score in node-negative and node-positive postmenopausal 
patients with breast cancer treated with anastrozole or tamoxifen: 
a TransATAC study. J Clin Oncol. 2010;28:1829–34.
 32. Mamounas EP, Tang G, Paik S, Bachner FL, Liu Q, Jeong J-H, 
et al: Prognostic impact of the 21-gene recurrence score (RS) 
on disease-free and overal survival of node-positive, ER positive 
breast cancer patients treates with adjuvant chemotherapy: results 
from NSABP B-28. J Clin Oncol. 2012,30:(27 suppl 1-1).
 33. Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, 
et al. Prognostic value of biologic subtype and the 21-gene recur-
rence score relative to local recurrence after breast conservation 
treatment with radiation for early stage breast carcinoma: results 
from the Eastern Cooperative Oncology Group E2197 study. 
Breast Cancer Res Treat. 2012;134:683–92.
 34. Roberts MC, Miller DP, Shak S, Petkov VI. Breast cancer-specific 
survival in patients with lymph node-positive hormone receptor-
positive invasive breast cancer and oncotype DX recurrence 
score results in the SEER database. Breast Cancer Res Treat. 
2017;163:303–10.
 35. Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, 
et al. West German Study Group Phase III PlanB Trial: first pro-
spective outcome data for the 21-gene recurrence score assay and 
concordance of prognostic markers by central and local pathology 
assessment. J Clin Oncol. 2016;34:2341–9.
 36. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery 
T, et al. Supervised risk predictor of breast cancer based on intrin-
sic subtypes. J Clin Oncol. 2009;27:1160–7.
 37. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, 
et al. A comparison of PAM50 intrinsic subtyping with immu-
nohistochemistry and clinical prognostic factors in tamoxifen-
treated estrogen receptor-positive breast cancer. Clin Cancer Res. 
2010;16:5222–32.
 38. Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Hor-
vath Z, et al. Predicting distant recurrence in receptor-positive 
breast cancer patients with limited clinicopathological risk: using 
the PAM50 Risk of Recurrence score in 1478 postmenopausal 
patients of the ABCSG-8 trial treated with adjuvant endocrine 
therapy alone. Ann Oncol. 2014;25:339–45.
 39. Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-
Knowles E, et al. Identifying clinically relevant prognostic sub-
groups of postmenopausal women with node-positive hormone 
receptor-positive early-stage breast cancer treated with endocrine 
therapy: a combined analysis of ABCSG-8 and ATAC using the 
 Clinical and Translational Oncology
1 3
PAM50 risk of recurrence score and intrinsic subtype. Ann. 
2015;26:1685–91.
 40. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, 
Cowens JW, et al. Comparison of PAM50 risk of recurrence score 
with oncotype DX and IHC4 for predicting risk of distant recur-
rence after endocrine therapy. J Clin Oncol. 2013;31:2783–90.
 41. Lænkholm A-V, Jensen M-B, Eriksen JO, Rasmussen BB, Knoop 
AS, Buckingham W, et al. PAM50 risk of recurrence score pre-
dicts 10-year distant Recurrence in a comprehensive danish cohort 
of postmenopausal women allocated to 5 years of endocrine 
therapy for hormone receptor-positive early breast cancer. J Clin 
Oncol. 2018;36:735–40.
 42. Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, 
et al. Comparison of the performance of 6 prognostic signatures 
for estrogen receptor-positive breast cancer: a secondary analysis 
of a randomized clinical trial. JAMA Oncol. 2018;4:545–53.
 43. Jensen M-B, Lænkholm A-V, Nielsen TO, Eriksen JO, Wehn P, 
Hood T, et al. The Prosigna gene expression assay and responsive-
ness to adjuvant cyclophosphamide-based chemotherapy in pre-
menopausal high-risk patients with breast cancer. Breast Cancer 
Res. 2018;20:79.
 44. Cardoso F, van’t Veer LJ, Veer LJ, Bogaerts J, Slaets L, Viale 
G, Delaloge S, et  al. 70-gene signature as an aid to treat-
ment decisions in early-stage breast cancer. N Engl J Med. 
2016;375:717–29.
 45. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, 
et al. A new molecular predictor of distant recurrence in ER-
positive, HER2-negative breast cancer adds independent infor-
mation to conventional clinical risk factors. Clin Cancer Res. 
2011;17:6012–20.
 46. Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krapp-
mann K, et  al. Comparison of EndoPredict and EPclin with 
Oncotype DX recurrence score for prediction of risk of distant 
recurrence after endocrine therapy. J Natl Cancer Inst. 2016. https 
://doi.org/10.1093/jnci/djw14 9.
 47. Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. 
The EndoPredict score provides prognostic information on late 
distant metastases in ER+/HER2− breast cancer patients. Br J 
Cancer. 2013;109:2959–64.
 48. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). 
Effects of chemotherapy and hormonal therapy for early breast 
cancer on recurrence and 15-year survival: an overview of the 
randomised trials. Lancet. 2005;365:1687–717.
 49. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. 
Long-term effects of continuing adjuvant tamoxifen to 10 years 
versus stopping at 5 years after diagnosis of oestrogen recep-
tor-positive breast cancer: aTLAS, a randomised trial. Lancet. 
2013;381:805–16.
 50. Gray R, Rea D, Handley D, Bowden S, Perry P. aTTom: long-term 
effects of continuing adjuvant tamoxifen to 10 years versus stop-
ping at 5 years in 6.953 women with early breast cancer. J Clin 
Oncol. 2013;31s:a:5.
 51. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 
Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Rel-
evance of breast cancer hormone receptors and other factors to 
the efficacy of adjuvant tamoxifen: patient-level meta-analysis of 
randomised trials. Lancet. 2011;378:771–84.
 52. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng 
I, et al. Tailoring adjuvant endocrine therapy for premenopausal 
breast cancer. N Engl J Med. 2018;379:122–37.
 53. LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, 
Ambroisine L, Davidson N, Jakesz R, Kaufmann M, et al. Use of 
luteinising-hormone-releasing hormone agonists as adjuvant treat-
ment in premenopausal patients with hormone-receptor-positive 
breast cancer: a meta-analysis of individual patient data from ran-
domised adjuvant trials. Lancet. 2007;369:1711–23.
 54. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, 
et al. Results of the ATAC (arimidex, tamoxifen, alone or in com-
bination) trial after completion of 5 years’ adjuvant treatment for 
breast cancer. Lancet. 2005;365:60–2.
 55. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, 
Goldhirsch A, Thürlimann B, Paridaens R, et al. Letrozole therapy 
alone or in sequence with tamoxifen in women with breast cancer. 
N Engl J Med. 2009;361:766–76.
 56. Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg 
EM-K, Liefers G-J, et al. Adjuvant tamoxifen and exemestane in 
women with postmenopausal early breast cancer (TEAM): 10-year 
follow-up of a multicentre, open-label, randomised, phase 3 trial. 
Lancet Oncol. 2017;18:1211–20.
 57. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, 
Fini A, et al. Switching to anastrozole versus continued tamoxifen 
treatment of early breast cancer: preliminary results of the Italian 
Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138–47.
 58. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Deloz-
ier T, et al. A randomized trial of exemestane after two to three 
years of tamoxifen therapy in postmenopausal women with pri-
mary breast cancer. N Engl J Med. 2004;350:1081–92.
 59. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch 
C, et al. Switching of postmenopausal women with endocrine-
responsive early breast cancer to anastrozole after 2 years’ adju-
vant tamoxifen: combined results of ABCSG trial 8 and ARNO 
95 trial. Lancet. 2005;366:455–62.
 60. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, 
et al. Late extended adjuvant treatment with letrozole improves 
outcome in women with early-stage breast cancer who complete 
5 years of tamoxifen. J Clin Oncol. 2008;26:1948–55.
 61. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, 
et al. Extended adjuvant therapy with anastrozole among post-
menopausal breast cancer patients: results from the randomized 
Austrian Breast and Colorectal Cancer Study Group Trial 6a. J 
Natl Cancer Inst. 2007;99:1845–53.
 62. Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de 
Carpentier M, Putter H, van den Bosch J, et al. Optimal duration 
of extended adjuvant endocrine therapy for early breast cancer; 
results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst. 
2018;110:40–8.
 63. Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, 
Dillmon MS, Frank ES, et al. Use of adjuvant bisphosphonates 
and other bone-modifying agents in breast cancer: a Cancer 
Care Ontario and American Society of Clinical Oncology Clini-
cal Practice Guideline. J Clin Oncol. 2017;35:2062–81.
 64. von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, 
Kümmel S, et al. Impact of treatment characteristics on response 
of different breast cancer phenotypes: pooled analysis of the 
German neo-adjuvant chemotherapy trials. Breast Cancer Res 
Treat. 2011;125:145–56.
 65. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wol-
mark N, et al. Pathological complete response and long-term 
clinical benefit in breast cancer: the CTNeoBC pooled analysis. 
Lancet. 2014;384:164–72.
 66. Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza 
A, Chacon JI, et al. Chemotherapy (CT) and hormonotherapy 
(HT) as neoadjuvant treatment in luminal breast cancer patients: 
results from the GEICAM/2006-03, a multicenter, randomized, 
phase-II study. Ann Oncol. 2012;23:3069–74.
 67. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer 
J-U, et al. Neoadjuvant treatment of postmenopausal breast can-
cer with anastrozole, tamoxifen, or both in combination: the 
immediate preoperative anastrozole, tamoxifen, or combined 
with tamoxifen (IMPACT) multicenter double-blind randomized 
trial. J Clin Oncol. 2005;23:5108–16.
Clinical and Translational Oncology 
1 3
 68. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. 
Randomized phase II neoadjuvant comparison between letro-
zole, anastrozole, and exemestane for postmenopausal women 
with estrogen receptor-rich stage 2 to 3 breast cancer: clinical 
and biomarker outcomes and predictive value of the baseline 
PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 
2011;29:2342–9.
 69. Prat A, Galvan P, Jimenez B, Buckingham W, Jeiranian HA, 
Schaper C, et al. Prediction of response to neoadjuvant chemo-
therapy using core needle biopsy samples with the Prosigna 
assay. Clin Cancer Res. 2016;22:560–6.
 70. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, 
Guarneri V, et al. Trastuzumab containing regimens for early 
breast cancer. Cochrane Database Syst Rev. 2012:CD006243.
 71. Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer 
CE, et al. Trastuzumab plus adjuvant chemotherapy for human 
epidermal growth factor receptor 2-positive breast cancer: 
planned joint analysis of overall survival from NSABP B-31 
and NCCTG N9831. J Clin Oncol. 2014;32:3744–52.
 72. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Gol-
dhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastu-
zumab after adjuvant chemotherapy in HER2-positive early breast 
cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 
Lancet. 2017;389:1195–205.
 73. Slamon D, Eiermann W, Robert N, Giermek J, Martín M, 
Jasiówka M, et al. Ten year follow-up of the BCIRG-006 trial 
comparing doxorubicin plus cyclophosphamide followed by doc-
etaxel (AC-T) with doxorubicin plus cyclophosphamide followed 
by docetaxel and trastuzumab (AC-TH) with docetaxel. Cancer 
Res. 2015;76(4_suppl):S5-04.
 74. Tolaney SM, Barry WT, Guo H, Dillon D, Dang CH-T, Yardley 
DA, et al. Seven-year follow-up of adjuvant paclitaxel (T) and 
trastuzumab (H) (APT trial) for node-negative, HER2-positive 
breast cancer. J Clin Oncol. 2017;15_suppl(15):511.
 75. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, 
et  al. Neratinib after trastuzumab-based adjuvant therapy in 
patients with HER2-positive breast cancer (ExteNET): a mul-
ticentre, randomised, double-blind, placebo-controlled, phase 3 
trial. Lancet Oncol. 2016;17:367–77.
 76. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, 
Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastu-
zumab in early HER2-positive breast cancer. N Engl J Med. 
2017;377:122–31.
 77. Earl H, Hiller L, Vallier A, Loi S, Howe D, Higgins H. PERSE-
PHONE: 6 versus 12  months (m) of adjuvant trastuzumab 
in patients (pts) with HER2 positive (+) early breast cancer 
(EBC): Randomised phase 3 non-inferiority trial with defini-
tive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol. 
2018;36:506.
 78. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, 
Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab 
followed by adjuvant trastuzumab versus neoadjuvant chemother-
apy alone, in patients with HER2-positive locally advanced breast 
cancer (the NOAH trial): a randomised controlled superiority trial 
with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.
 79. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu 
M-C, et  al. Efficacy and safety of neoadjuvant pertuzumab 
and trastuzumab in women with locally advanced, inflamma-
tory, or early HER2-positive breast cancer (NeoSphere): a ran-
domised multicentre, open-label, phase 2 trial. Lancet Oncol. 
2012;13:25–32.
 80. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, 
et al. Pertuzumab plus trastuzumab in combination with stand-
ard neoadjuvant anthracycline-containing and anthracycline-free 
chemotherapy regimens in patients with HER2-positive early 
breast cancer: a randomized phase II cardiac safety study (TRY-
PHAENA). Ann Oncol. 2013;24:2278–84.
 81. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck 
AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early 
human epidermal growth factor receptor 2–positive breast can-
cer: results from the randomized phase III adjuvant lapatinib 
and/or trastuzumab treatment optimization trial. J Clin Oncol. 
2016;34:1034–42.
 82. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge 
SB, et al. Outcomes by tumor subtype and treatment pattern in 
women with small, node-negative breast cancer: a multi-institu-
tional study. J Clin Oncol. 2014;32:2142–50.
 83. Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert 
C, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoad-
juvant chemotherapy for early breast cancer (GeparSepto-GBG 
69): a randomised, phase 3 trial. Lancet Oncol. 2016;17:345–56.
 84. Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mas-
tro L, et al. Platinum-based neoadjuvant chemotherapy in triple-
negative breast cancer: a systematic review and meta-analysis. 
Ann Oncol. 2018;29:1497–508.
 85. Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. 
Adjuvant capecitabine for breast cancer after preoperative chemo-
therapy. N Engl J Med. 2017;376:2147–59.
 86. Natori A, Ethier J-L, Amir E, Cescon DW. Capecitabine in early 
breast cancer: a meta-analysis of randomised controlled trials. Eur 
J Cancer. 2017;77:40–7.
 87. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, 
Cowens-Alvarado RL, et al. American Cancer Society/American 
Society of Clinical Oncology Breast Cancer Survivorship Care 
Guideline. CA Cancer J Clin. 2016;66:43–73.
 88. Sisler J, Chaput G, Sussman J, Ozokwelu E. Follow-up after treat-
ment for breast cancer: practical guide to survivorship care for 
family physicians. Can Fam Physician. 2016;62:805–11.
 89. Barnadas A, Algara M, Cordoba O, Casas A, Gonzalez M, Marzo 
M, et al. Recommendations for the follow-up care of female 
breast cancer survivors: a guideline of the Spanish Society of 
Medical Oncology (SEOM), Spanish Society of General Medi-
cine (SEMERGEN), Spanish Society for Family and Community 
Medicine (SEMFYC), Spanish Society for General and Family 
Physicians (SEMG), Spanish Society of Obstetrics and Gynecol-
ogy (SEGO), Spanish Society of Radiation Oncology (SEOR), 
Spanish Society of Senology and Breast Pathology (SESPM), 
and Spanish Society of Cardiology (SEC). Clin Transl Oncol. 
2018;20:687–94.
 90. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl 
S, et al. De-escalating and escalating treatments for early-stage 
breast cancer: the St. Gallen International Expert Consensus Con-
ference on the Primary Therapy of Early Breast Cancer 2017. Ann 
Oncol. 2017;28:1700–12.
